Overview
A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model
Status:
Completed
Completed
Trial end date:
2017-12-18
2017-12-18
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will assess the pharmacodynamic effects of SAGE-217 in approximately 42 healthy adult subjects using an insomnia model.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Sage Therapeutics
Criteria
Inclusion Criteria:- Subject is willing and able to participate in the study, including all assessments,
planned inpatient stays and all follow-up visits
- Subject is a healthy, ambulatory volunteer
- Subject meets sleep Qualification criteria
Exclusion Criteria:
- Subject has a medical history of suicidal behavior, epilepsy, eating disorders, sleep
disorders, or circadian rhythm disorders
- Subject has worked a night shift or flown >1 time zone within 30 days prior to
Screening